A Single-arm Phase II Trial of Intermittent Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Phase of Trial: Phase II
Latest Information Update: 14 May 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 07 Aug 2017 Status changed from not yet recruiting to recruiting.
- 17 Jul 2017 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.